

Nectar Lifesciences Ltd.



Ref No. NLL/CS/2012-103

Dated: 09.08.2012

1. National Stock Exchange of India Limited
'G' Block, Exchange Plaza, Bandra Kurla Complex,
Bandra (East), MUMBAI - 400 051.
2. Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers, Dalal Street,
MUMBAI - 400 001.

Sub: Compliance under Clause 41 the Listing Agreement.

Sirs,

As required under Clause 41 of the Listing Agreement, the Auditors of the company have conducted the limited review of the Unaudited Financial Results of the company for the quarter ended on 30th June, 2012. A copy of the Limited Review Report is enclosed herewith for your record please.

Kindly acknowledge receipt of the same and oblige.

Thanking you,

Yours faithfully,

For NECTAR LIFESCIENCES LIMITED

Sunder Lal
Company Secretary

Encl. as above



To Whom It May Concern

We have reviewed the accompanying statement of unaudited financial results of Nectar Lifesciences Limited for the quarter ended June 30, 2012 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Chandigarh

Date: 09-08-2012

For Datta Singla & Company
Chartered Accountants
CHARTERED
ACCOUNTANTS
Partner's Name: JOGESH MONSA
CHANDIGARH
Membership No.: 099813.





NECTAR LIFESCIENCES LIMITED

Regd. Office: Vill. Saidpura, Tehsil Derabassi, Distt. Mohali, (Punjab)

Part I - Financial Results for the Quarter ended 30.06.2012 and for the year ended 31.03.2012

(Rs in Lacs)

S. No	PARTICULARS	Quarter ended 30.06.2012	Quarter ended 31.03.2012	Quarter ended 30.06.2011	Year ended 31.03.2012	Year ended 31.03.2011	Year ended 31.03.2012	Year ended 31.03.2011
		Unaudited (Stand-alone)	Unaudited (Stand-alone)	Unaudited (Stand-alone)	Audited (Stand-alone)	Audited (Stand-alone)	Audited (Consolidated)	Audited (Consolidated)
1.	Income from Operations							
	(a) Gross Sales	40413.21	40567.83	21907.37	134173.78	111577.03	134173.78	111577.03
	Less : Excise Duty	1058.21	1188.27	1017.83	3845.02	6032.19	3845.02	6032.19
	Net Sales	39355.00	39379.56	20889.54	130328.76	105544.84	130328.76	105544.84
	(b) Other Operating Income	61.85	311.00	240.58	981.84	661.44	981.84	661.44
	Total Income from Operations (net)	39416.85	39690.56	21130.12	131310.60	106206.28	131310.60	106206.28
2.	Expenses							
	(a) Cost of Materials consumed	24266.62	32435.05	11647.87	99060.46	71039.76	99060.46	71039.76
	(b) Purchase of Stock in Trade	3499.86	1679.71	1136.00	6302.74	8299.68	6302.74	8299.68
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	1481.01	(5351.91)	478.57	(13466.91)	(8232.45)	(13466.91)	(8232.45)
	(d) Employee benefits expense	1075.06	1029.97	1240.35	4765.86	3716.81	4765.86	3716.81
	(e) Depreciation and amortisation expense	1792.60	1431.86	1225.34	6072.94	4609.59	6072.94	4609.59
	(f) Other expenses	3056.30	3048.38	2141.07	11018.76	8694.38	11022.18	8665.84
	Total Expenses	35171.45	34273.06	17869.20	113753.85	88127.77	113757.27	88099.23
3.	Profit from Operations before Other Income, finance costs and exceptional Items (1-2)	4245.40	5417.50	3260.92	17556.75	18078.51	17553.33	18107.05
4.	Other Income	411.99	372.78	0.08	1289.40	1345.58	1289.40	1345.58
5.	Profit before finance costs and exceptional Items (3+4)	4657.39	5790.28	3261.00	18846.15	19424.09	18842.73	19452.63
6.	Finance costs	2492.77	3754.96	1960.36	10299.51	7408.40	10299.51	7408.85
7.	Profit after finance costs but before exceptional Items (5-6)	2164.62	2035.32	1300.64	8546.64	12015.69	8543.22	12043.78
8.	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00	0.00
9.	Profit from ordinary activities before tax (7+8)	2164.62	2035.32	1300.64	8546.64	12015.69	8543.22	12043.78
10.	Tax Expense	561.85	490.33	178.66	1221.64	1623.81	1221.64	1623.81
11.	Net Profit from ordinary activities after tax (9-10)	1602.77	1544.99	1121.98	7325.00	10391.88	7321.58	10419.97
12.	Extraordinary Item (net of tax expense)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
13.	Net Profit for the period (11-12)	1602.77	1544.99	1121.98	7325.00	10391.88	7321.58	10419.97
14.	Paid up Equity Share Capital (Face Value per share : Re.1/-)	2242.61	2242.61	2242.61	2242.61	2242.61	2242.61	2242.61
15.	Reserves excluding Revaluation Reserves				76,212.05	69,875.74	76,203.71	69,870.68
16.i	Earnings per Share (EPS) (before extraordinary items)							
	a) Basic	0.71	0.69	0.50	3.27	4.63	3.26	4.65
	b) Diluted	0.71	0.69	0.50	3.27	4.63	3.26	4.65
16.ii	Earnings per Share (EPS) (after extraordinary items)							
	a) Basic	0.71	0.69	0.50	3.27	4.63	3.26	4.65
	b) Diluted	0.71	0.69	0.50	3.27	4.63	3.26	4.65




Part II Select Information for the Quarter ended 30.06.2012 and Year Ended 31.03.2012

A Particulars of shareholding								
1. Public Shareholding								
- Number of Shares	124792970	124792970	124896970	124792970	124969970	124792970	124969970	
- Percentage of Shareholding	55.65	55.65	55.69	55.65	55.73	55.65	55.73	
2. Promoters and Promoter Group Shareholding								
a) Pledged/Encumbered								
- Number of Shares	0	0	0	0	0	0	0	
- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
- Percentage of Shares (as a % of the total share capital of the company)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
b) Non-encumbered								
- Number of Shares	99468000	99468000	99364000	99468000	99291000	99468000	99291000	
- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00	100.00	
- Percentage of Shares (as a % of the total share capital of the company)	44.35	44.35	44.31	44.35	44.27	44.35	44.27	
B Investor Complaints	3 Months ended 30.06.2012							
Pending at the beginning of Quarter	0							
Received During the Quarter	15							
Disposed Off During the Quarter	15							
Pending at the end of Quarter	0							

Statement of Assets and Liabilities

(Rs in Lacs)

PARTICULARS	As at	As at	As at	As at
	31.03.2012	31.03.2011	31.03.2012	31.03.2011
	Audited	Audited	Audited	Audited
	(Stand-alone)	(Stand-alone)	(Consolidated)	(Consolidated)
SHAREHOLDERS' FUND				
(i) Capital	2,242.61	2,242.61	2,242.61	2,242.61
(ii) Reserves and Surplus	76,212.05	69,875.74	76,203.71	69,870.68
NON CURRENT LIABILITIES				
(i) Long Term Liabilities	36,361.74	23,434.15	36,361.74	23,434.15
(ii) Deferred Tax Liability	6,302.21	5,080.56	6,302.21	5,080.56
(ii) Other Long Term Liabilities	195.68	110.83	195.68	110.83
(iii) Long Term Provisions	342.63	241.06	342.63	241.06
CURRENT LIABILITIES				
(i) Short Term Borrowings	56,521.15	33,001.01	56,521.15	33,001.01
(ii) Trade Payables	19,449.11	13,982.06	19,449.11	13,983.21
(iii) Other Current Liabilities	12,984.30	24,592.34	12,986.90	24,592.96
(iv) Short Term Provisions	1,481.37	8,701.67	1,481.37	8,701.67
	2,12,092.85	1,81,262.03	2,12,087.11	1,81,258.74
NON CURRENT ASSETS				
(i) Fixed Assets (Incl CWIP)	1,00,800.54	81,867.57	1,00,800.54	81,867.57




(ii) Non Current Investments	5.01	5.01	5.01	5.01
(iii) Long Term Loans & Advances	6,318.50	4,986.94	6,312.20	4,983.65
(iv) Other Non Current Assets	2.25	3.00	2.25	3.00
CURRENT ASSETS				
(i) Current Investments	14.11	533.17	14.11	533.17
(ii) Inventories	59,141.59	47,088.48	59,141.59	47,088.48
(iii) Trade Receivables	30,449.27	31,112.85	30,449.27	31,112.85
(iv) Cash & Bank Balances	2,592.48	3,257.49	2,592.48	3,257.49
(v) Short Term Loans & Advances	10,504.17	10,202.95	10,504.73	10,202.95
(vi) Other Current Assets	2,264.93	2,204.57	2,264.93	2,204.57
	2,12,092.85	1,81,262.03	2,12,087.11	1,81,258.74

Notes:

1. The above financial results were reviewed by Audit Committee on 09.08.12 and approved by the Board in its meeting held on even date i.e. 09.08.12 and further limited reviewed by the Statutory Auditors of the Company.
2. The company is exclusively in the pharmaceutical business segment.
3. The Board of Directors has recommended the Final Dividend of Re. 0.10/- per equity share (10% on the face value of Re. 1/- per equity share) to the Members of the Company, out of profits of the Company for the financial year 2011-12.
4. Previous year figures have been regrouped and reclassified wherever necessary to make them comparable with current period.

Dated: 09.08.2012

Place: Chandigarh



By Order of the Board of Directors
of Nectar Lifesciences Limited

(Sanjiv Goyal)
Chairman & Managing Director